Nonrenounceable entitlement offer to raise up to approximately $10 million (before direct offer costs).
The offer is for 2 new fully paid ordinary shares (New Shares) for every 3 existing Shares held
Offer price of $0.028 per new share, a 31.7% discount to the closing price of Chimeric shares on 24 October 2023.
Following successful completion, this will provide for the continuing advancement of the Company’s drug development program, with four ongoing clinical trials in cell therapy.
All Directors intend to participate in the Offer.
Chimeric believes that an entitlement offer will benefit shareholders who want to maintain their proportional ownership in the Company, as we believe our shareholders should have the first right to participate in the growth of the Company and continue the journey to maximising shareholder wealth.
A non-renounceable entitlement offer is a type of capital raising method used by companies to raise funds from existing shareholders. In this offer, existing shareholders are given the opportunity to purchase additional shares in the company at a discounted price.
However, unlike a renounceable entitlement offer, shareholders cannot sell their entitlements on the market if they do not wish to participate in the offer.
If you have additional questions about the offer, please submit your questions below and one of our Team will be in touch with you shortlyContact Us